Similar to previous reports on other HDAC inhibitors, the present study also found that MHC class I presentation was upregulated by OBP-801 in a dose-dependent manner, and this upregulation was suppressed by LMP2 knockdown in all ccRCC cell lines. Here, HDAC9 is linked to nonpapillary renal cell carcinoma.